Archives of gynecology and obstetrics
-
Arch. Gynecol. Obstet. · Jul 2009
Randomized Controlled Trial Comparative StudyComparative efficacy and safety of vaginal misoprostol versus dinoprostone vaginal insert in labor induction at term: a randomized trial.
To compare efficacy and safety of vaginal misoprostol (PGE(1) analog) with dinoprostone (PGE(2) analog) vaginal insert for labor induction in term pregnancies. ⋯ Using vaginal misoprostol is an effective way of labor induction in term pregnant women with unfavorable cervices, since it is associated with a shorter duration of labor induction and higher rates of vaginal delivery within 12 h. Misoprostol and dinoprostone are equally safe, since misoprostol did not result in a rise in maternal and neonatal morbidity, namely, tachysystole, uterine hyperstimulation, cesarean section rates and admission to neonatal intensive care units as reported previously in literature.
-
Arch. Gynecol. Obstet. · Jul 2009
Case ReportsCaesarean delivery in a parturient with Holt-Oram syndrome and implantable cardioverter defibrillator: anaesthetic considerations.
Holt-Oram syndrome is a rare autosomal dominant disorder characterized by skeletal upper-limb dysplasias and congenital cardiac defects. Clinical manifestations of this syndrome vary, and range from sub clinical radiologic findings to overt, life-threatening disease. ⋯ Concerns with regards to anaesthetic management include problems with vascular access, possible arrhythmias, the presence of an AICD, and the possibility of cardiovascular instability. The characteristics of this syndrome and anaesthetic implications are discussed.
-
Arch. Gynecol. Obstet. · Jul 2009
Case ReportsFactor VIIa treatment of DIC as a clinical manifestation of amniotic fluid embolism in a patient with fetal demise.
A pregnant patient, with term intrauterine fetal demise, who developed cardiopulmonary arrest during labor, followed by disseminated intravascular coagulation (DIC) secondary to amniotic fluid embolism (AFE) that was treated with Recombinant Factor VIIa, is presented. ⋯ Recombinant Factor VIIa may be a treatment option for hemorrhage in patients with DIC related to AFE.